Cost-Effectiveness Analysis of Telemedicine to Evaluate Diabetic Retinopathy in a Prison Population

Diabetes Care

Volumn 27, Issue 5, 2004, Pages 1095-1101

  Aoki, Noriaki ^a,b,g   Dunn, Kim ^a,c   Fukui, Tsuguya ^d   Beck, J Robert ^e   Schull, William J ^c   Li, Helen K ^f  

^a University of Texas School of Health Information Sciences at Houston   (United States)

^b Center for Health Management   (Japan)

^c Schull Institute   (United States)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e FOX CHASE CANCER CENTER   (United States)

^f University of Texas Medical Branch School of Medicine   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLINDNESS; CASE REPORT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; FOLLOW UP; HEALTH CARE COST; HUMAN; LASER COAGULATION; MALE; MONTE CARLO METHOD; PREVALENCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA EDEMA; RETINOPATHY; SCREENING TEST; TELECOMMUNICATION;

BLINDNESS; COSTS AND COST ANALYSIS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; PREVALENCE; PRISONERS; PRISONS; TELEMEDICINE; TEXAS;

EID: 2342578941     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.5.1095     Document Type: Article

References (36)

1. Robertson JM: The disease profile of Texas prison inmates. Ann Epidemiol 10:71-73, 2000
2. Baillargeon J, Black SA, Pulvino J, Dunn K: The disease profile of Texas prison inmates. Ann Epidemiol 10:74-80, 2000
3. Anno B: Health behavior in prisons and correctional facilities. In Handbook of Health Behavioral Research. Gochmann DS, Ed. New York, Plenum Publishing, 1997
4. Diabetes in America. Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1995
5. Lambert M: Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 125:939, 1996
6. Javitt JC, Aiello LP: Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 124:164-169, 1996
7. Fendrick AM, Javitt JC, Chiang YP: Cost-effectiveness of the screening and treatment of diabetic retinopathy: what are the costs of underutilization? Int J Technol Assess Health Care 8:694-707, 1992
8. Vijan S, Hofer TP, Hayward RA: Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 283:889-896, 2000
9. Cost-Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russel LB, Weinstein MC, Eds. New York, Oxford University Press, 1996
10. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 13:322-338, 1993
11. Petitti DB: Meta-analysis, decision analysis, and cost-effectiveness analysis. New York, Oxford University Press, 2000
12. Younis N, Broadbent DM, Vora JP, Harding SP: Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 361:195-200, 2003
13. Moss SE, Klein R, Klein BE: The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105:998-1003, 1998
14. Blankenship GW: Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology 98:125-128, 1991
15. Ferris FL: How effective are treatments for diabetic retinopathy? JAMA 269:1290-1291, 1993
16. Vander JF, Duker JS, Benson WE, Brown GC, McNamara JA, Rosenstein RB: Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 98:1575-1579, 1991
17. Klein R, Moss SE, Klein BE, DeMets DL: Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med 149: 266-272, 1989
18. Davis MD, Hiller R, Magli YL, Podgor MJ, Ederer F, Harris WA, Long JW, Haug GA: Prognosis for life in patients with diabetes: relation to severity of retinopathy. Trans Am Ophthalmol Soc 77:144-170, 1979
19. Knatterud GL: Mortality experience in the diabetic retinopathy study. Isr J Med Sci 19:424-428, 1983
20. American Academy of Ophthalmology Quality of Care Committee: Preferred Practice Pattern: Diabetic Retinopathy. San Fransisco, CA, American Academy of Ophthalmology, 1993
21. Klein R, Klein BE, Neider MW, Hubbard LD, Meuer SM, Brothers RJ: Diabetic retinopathy as detected using ophthalmoscopy, a nonmydriatic camera and a standard fundus camera. Ophthalmology 92:485-491, 1985
22. Moss SE, Klein R, Kessler SD, Richie KA: Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 92:62-67, 1985
23. Fransen SR, Leonard-Martin TC, Feuer WJ, Hildebrand PL: Clinical evaluation of patients with diabetic retinopathy: accuracy of the Inoveon diabetic retinopathy-3DT system. Ophthalmology 109:595-601, 2002
24. Lin DY, Blumenkranz MS, Brothers RJ, Grosvenor DM: The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol 134:204-213, 2002
25. Beck JR, Kassirer JP, Pauker SG: A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 73:883-888, 1982
26. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP: A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 73: 889-897, 1982
27. Torrance GW: Utility approach to measuring health-related quality of life. J Chronic Dis 40:593-603, 1987
28. Torrance GW, Feeny D: Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5:559-575, 1989
29. Froberg DG, Kane RL: Methodology for measuring health-state preferences. I. Measurement strategies. J Clin Epidemiol 42:345-354, 1989
30. Brown MM, Brown GC, Sharma S, Shah G: Utility values and diabetic retinopathy. Am J Ophthalmol 128:324-330, 1999
31. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S: Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health-care reform. Diabetes Care 17:909-917, 1994
32. Chiang YP, Bassi LJ, Javitt JC: Federal budgetary costs of blindness. Milbank Q 70:319-340, 1992
33. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ: Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 5:157-177, 1985
34. Pass TM, Goldstein LP: A computerized aid for medical cost-effectiveness analysis (Abstract). Med Decis Making 1:465, 1981
35. Pasta DJ, Taylor JL, Henning JM: Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori. Med Decis Making 19:353-363, 1999
36. Aoki N, Beck JR, Kitahara T, Ohbu S, Soma K, Ohwada T, Cone RW, Fukui T: Reanalysis of unruptured intracranial aneurysm management: effect of a new international study on the threshold probabilities. Med Decis Making 21:87-96, 2001